ingest
cdrApp
2017-08-15T23:03:40.041Z
d91e81c8-5a8a-4e8a-976c-cad4e396e5ee
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2017-08-15T23:04:32.449Z
Setting exclusive relation
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2017-08-15T23:04:41.476Z
Setting exclusive relation
addDatastream
MD_TECHNICAL
fedoraAdmin
2017-08-15T23:04:50.539Z
Adding technical metadata derived by FITS
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2017-08-15T23:05:08.414Z
Setting exclusive relation
addDatastream
MD_FULL_TEXT
fedoraAdmin
2017-08-15T23:05:18.195Z
Adding full text metadata extracted by Apache Tika
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2017-08-15T23:05:36.224Z
Setting exclusive relation
modifyDatastreamByValue
RELS-EXT
cdrApp
2017-08-22T13:58:21.007Z
Setting exclusive relation
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-01-25T05:41:25.255Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-01-27T06:09:35.167Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-03-14T02:19:18.133Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-05-17T14:09:20.516Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-07-11T00:50:51.457Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-07-17T20:50:59.180Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-08-08T20:16:09.882Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-08-15T17:25:05.848Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-08-16T20:27:15.135Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-09-21T17:51:12.579Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-09-26T21:02:40.112Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-10-11T21:41:23.147Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2019-03-20T15:13:39.537Z
Laura
Hester
Author
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality.
We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims.
Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients.
In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly.
This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
Spring 2017
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults
Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological
malignancies that are broadly categorized into aggressive or indolent tumor growth groups.
In the past two decades, there have been notable increases in the proportion of NHL
diagnoses aged >65 and cancer-specific survival with the aging US population and
improvements in NHL treatments. These population changes have important implications for
non-cancer mortality, particularly for indolent NHL subtypes, which display
remitting-relapsing patterns and a slower progression. This dissertation sought to address
gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on:
1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2)
characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We
identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from
2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results
(SEER) cancer registry with Medicare health insurance claims. Using death certificate data
and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of
NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity
level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded
non-cancer mortality across all ages and comorbidity levels. In indolent subtypes,
non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with
older ages, higher comorbidity burdens, or specific subtypes. The results support
development of tools predicting non-cancer mortality in older indolent NHL patients. In
Aim 2, we developed and internally validated risk prediction models for short- and
long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net
penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality
(four models per outcome) in 100 randomly resampled training sets. In 100 validation sets,
we compared average performance statistics of the elastic net to those from comorbidity
score models. For all outcomes, the elastic net models had a higher discrimination and
lower false-positive rate than comorbidity score models. However, differences were not
statistically significantly. This project supports development of personalized prediction
models integrated into electronic medical records that can inform physicians and patients
on non-cancer mortality risk in indolent NHL treatment decision-making.
Spring 2017
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty,
non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting
institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
Spring 2017
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017-05
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
University of North Carolina at Chapel Hill
Degree granting institution
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging; comorbidities; competing risks; frailty; non-Hodgkin lymphoma; penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging, comorbidities, competing risks, frailty, non-Hodgkin lymphoma, penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Epidemiology
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Laura
Hester
Creator
Department of Epidemiology
Gillings School of Global Public Health
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) consists of heterogeneous hematological malignancies that are broadly categorized into aggressive or indolent tumor growth groups. In the past two decades, there have been notable increases in the proportion of NHL diagnoses aged >65 and cancer-specific survival with the aging US population and improvements in NHL treatments. These population changes have important implications for non-cancer mortality, particularly for indolent NHL subtypes, which display remitting-relapsing patterns and a slower progression. This dissertation sought to address gaps in knowledge about non-cancer mortality in NHL by providing foundational evidence on: 1) cancer-specific and non-cancer mortality patterns in NHL subtypes and 2) characteristics of indolent NHL patients at greatest risk of non-cancer mortality. We identified adults aged >66 at diagnosis with a first, primary NHL diagnosis from 2004-2011 using a database linking the US Surveillance, Epidemiology, and End Results (SEER) cancer registry with Medicare health insurance claims. Using death certificate data and Fine-Gray competing risks methods, Aim 1 estimated the 5-year cumulative incidence of NHL-specific and non-cancer mortality by prognostic factors (subtype, age, comorbidity level) in 26,809 NHL patients. Among aggressive subtypes, NHL-specific mortality exceeded non-cancer mortality across all ages and comorbidity levels. In indolent subtypes, non-cancer mortality was similar to or exceeded NHL-specific mortality for patients with older ages, higher comorbidity burdens, or specific subtypes. The results support development of tools predicting non-cancer mortality in older indolent NHL patients. In Aim 2, we developed and internally validated risk prediction models for short- and long-term mortality outcomes in 9789 indolent NHL patients. We created 16 elastic net penalized regression models predicting 1- and 5-year all-cause and non-cancer mortality (four models per outcome) in 100 randomly resampled training sets. In 100 validation sets, we compared average performance statistics of the elastic net to those from comorbidity score models. For all outcomes, the elastic net models had a higher discrimination and lower false-positive rate than comorbidity score models. However, differences were not statistically significantly. This project supports development of personalized prediction models integrated into electronic medical records that can inform physicians and patients on non-cancer mortality risk in indolent NHL treatment decision-making.
2017
Epidemiology
Public health
Oncology
aging; comorbidities; competing risks; frailty; non-Hodgkin lymphoma; penalized regression prediction models
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Jennifer
Lund
Thesis advisor
Til
Stürmer
Thesis advisor
M. Alan
Brookhart
Thesis advisor
Steven
Park
Thesis advisor
William
Wood
Thesis advisor
text
2017-05
Hester_unc_0153D_17176.pdf
uuid:1b034fd1-2937-4186-bc12-8e173d32d611
2017-06-22T15:38:48Z
proquest
2019-08-15T00:00:00
application/pdf
3637518
yes